Clinical validation of the Dry Blood Spot (DBS) method for risperidone, aripiprazole, pipamperone and its major metabolites

Clinical validation of the Dry Blood Spot (DBS) method for risperidone, aripiprazole, pipamperone and its major metabolites - DAPpeR: Dried blood spot of Aripiprazole, Pipamperone, Risperidone

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45799

Enrollment

120

Registered

2016-05-17

Start date

2016-06-09

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nvt

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - using either aripiprazole, risperidone, paliperidone or pipamperone - 18 years or older

Exclusion criteria

Exclusion criteria: nvt

Design outcomes

Primary

Measure	Time frame
the main study parameter is the agreement between antipsychotic drug plasma levels of blood collected by venipuncture or DBS, both measured by ultra-performance liquid chromatography tandem mass-spectrometry (UHPLC-MS/MS) .	—

Secondary

Measure	Time frame
Covariates influencing through levels	—

Countries

Netherlands

Outcome results